TPD52 and prostate carcinoma: The mechanism is that circ‐XIAP can directly target miR‐1182 and subsequently promote multidrug resistance in prostate cancer by regulating the miR‐1182/TPD52 axis, which is a promising therapeutic target for prostate cancer chemotherapy.745